ArticleInflammatory bowel diseases2022

Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study.

Jurij Hanzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.